Palliative chemotherapy for patients with breast cancer
Mené sur 852 patientes atteintes d'un cancer du sein de stade métastatique ou localement récidivant ayant été traité à l'aide d'une anthracycline, d'un taxane et de capécitabine, cet essai international randomisé de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'etirinotecan pegol
In recent years, the survival of women with metastatic breast cancer has improved substantially thanks to advances in both cancer-specific management and supportive care. As a result of prolonged survival and the availability of many and better-tolerated drugs, most women with metastatic breast cancer will be eligible for several lines of chemotherapy. Indeed, clinicians in the USA reported in a survey that they recommend an average of four to six lines of chemotherapy for their patients with metastatic breast cancer.
The Lancet Oncology 2015